Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab Prolongs OS Among Patients with Early-Stage TNBC By Ogkologos - November 8, 2024 632 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-522 study Source RELATED ARTICLESMORE FROM AUTHOR Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers MOST POPULAR Early-Stage and Locally Advanced NSCLC: ESMO Clinical Practice Guideline August 28, 2025 ESMO Manifesto – Translating Scientific Evidence Into Effective Public Health Policy October 20, 2023 Survivor Sees Mom Fighting Breast Cancer At Brunch And Pays For... December 2, 2019 ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of... July 1, 2025 Load more HOT NEWS Adding Durvalumab to First-Line Platinum-Based Chemotherapy Followed by Maintenance Durvalumab With... Healthy and Delicious Figs An Important Part of Cancer Caregiving That’s Often Overlooked and How... Addressing Disparities and Raising Awareness During National Black Family Cancer Awareness...
